Resonance Health Adds Resolutions to Ratify 83.3 Million Share Placement at $0.072 Per Share

Shwetambri Chauhan

06 November 2026 05:39 PM AEDT

Resonance Health Adds Resolutions to Ratify 83.3 Million Share Placement at $0.072 Per Share

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Resonance Health Limited (ASX:RHT) has issued an addendum to its Notice of Annual General Meeting dated 14 October 2026, adding two new resolutions seeking shareholder ratification of a prior placement of 83,333,319 shares at an issue price of $0.072 per share, raising approximately $6,000,000 before costs.

Key Points

Two additional resolutions — Resolutions 9 and 10 — have been added to the AGM scheduled for 10:00am (AWST) on 19 November 2026
Resolution 9 seeks ratification of 35,621,296 placement shares issued under Listing Rule 7.1; Resolution 10 seeks ratification of 47,712,023 placement shares under Listing Rule 7.1A
Bell Potter Securities Limited acted as lead manager, with a management fee of 2% and selling fee of 3% of gross proceeds, totalling approximately $300,000 exclusive of GST
Replacement proxy forms must be received by no later than 10:00am (AWST) on Tuesday, 17 November 2026

Placement Terms and Bell Potter Engagement

According to the filing, the company announced on 27 October 2026 that it had received firm commitments from institutional, professional and sophisticated investors for the placement of 83,333,319 shares at $0.072 per share to raise approximately $6,000,000 before costs. No options or other securities will be issued with the placement shares. Bell Potter Securities Limited acted as lead manager and will be reimbursed for reasonable out-of-pocket expenses, including legal fees of up to $40,000. The company has also granted Bell Potter a right of first refusal to act as lead manager to any equity capital raising undertaken within 12 months following completion of the placement.

Intended Use of Placement Funds

The filing states that the company intends to apply funds raised under the placement towards three growth programmes: MRI endpoint acceleration, the expansion of its TrialsWest east coast network, and the development of its non-invasive liver fibrosis device. The funds will also be directed to working capital and the costs of the placement. The placement shares are expected to be issued on or about 9 November 2026, prior to the date of the meeting. The addendum notes the placement was announced on 27 October 2026 and was made to institutional, professional and sophisticated investors.

Proxy and Voting Arrangements for Additional Resolutions

The filing sets out that shareholders who have already returned the original proxy form and do not wish to change their votes on Resolutions 1 to 8 or vote on the additional resolutions are not required to take any action. Those wishing to vote on Resolutions 9 and 10 must complete and return the replacement proxy form by 10:00am (AWST) on 17 November 2026. Voting exclusions apply to persons who participated in the placement issue, in accordance with Listing Rule 14.11. The addendum states it is supplemental to the original notice and should be read in conjunction with it, with all original resolutions remaining unchanged.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.